MYRIAD GENETICS INC

Myriad Genetics Inc. specializes in advanced molecular diagnostics, delivering clinically validated genomic testing services primarily for veterans’ healthcare needs. Their core capability centers on the deployment of proprietary prognostic assays—such as PROLARIS—that analyze gene expression patterns to guide personalized treatment decisions in oncology, particularly for prostate cancer. The company leverages next-generation sequencing platforms and bioinformatics pipelines to transform tissue samples into actionable clinical insights, enabling precision medicine applications within institutional care settings. Their technical expertise includes validated laboratory-developed tests (LDTs), CLIA-certified laboratory operations, and regulatory-compliant data interpretation workflows tailored to federal healthcare environments. Key differentiators include high-throughput genomic analysis, reproducible biomarker validation, and seamless integration of test results into electronic health record systems used by veteran-facing providers. Myriad Genetics consistently supports the Department of Veterans Affairs, providing genomic diagnostic services that inform clinical pathways for veteran patients. Their work with the VA is focused on expanding access to precision oncology tools within the Veterans Health Administration network, ensuring evidence-based, risk-stratified care delivery. The recurring nature of their engagements suggests a trusted, operational partnership rooted in clinical utility and outcomes-driven testing protocols. The contractor operates primarily under NAICS 621511, which defines medical laboratories performing diagnostic testing on human specimens. In practice, this means they function as a high-complexity clinical lab offering molecular diagnostics, not routine clinical testing. Their market positioning is niche but critical: they serve as a specialized provider of genomic medicine solutions within the federal healthcare ecosystem, filling a gap between broad laboratory services and targeted cancer care innovation. Myriad Genetics Inc. is a private, for-profit entity headquartered in Salt Lake City, Utah, with no publicly disclosed federal certifications. Their geographic presence is anchored in Utah, but their diagnostic services are delivered nationally through laboratory networks supporting federal beneficiaries. They maintain a focused government market presence through direct, repeat engagements with the VA.